Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Chemoembolization kills tumor
cells by blocking the blood flow to the tumor and keeping chemotherapy drugs, such as
doxorubicin, near the tumor. Giving sunitinib together with chemoembolization may kill more
tumor cells.
PURPOSE: This phase II trial is studying how well giving sunitinib together with
chemoembolization works in treating patients with liver cancer that cannot be removed by
surgery.